BioCentury
ARTICLE | Distillery Therapeutics

Cancer

May 15, 2018 6:06 PM UTC

Mouse studies suggest nanoparticles loaded with an ADORA2A antagonist and conjugated to CAR T cells could help treat ovarian cancer. The conjugate consists of cross-linked multilamellar liposomal nanoparticles loaded with a tool compound ADORA2A antagonist and linked to CAR T cells with a maleimide-thiol bridge. In a mouse model of ovarian cancer, the conjugate decreased tumor growth and increased T cell engraftment in the tumor and survival compared with the CAR T cells alone or the unconjugated antagonist-loaded liposomes and CAR T cells. In a mouse model of ovarian cancer pretreated with CAR T cells, the conjugate decreased tumor size and increased the number of tumor-infiltrating T cells, including the CAR T cells. Next steps could include testing the conjugate in models of other cancers.

Kyowa Hakko Kirin Co. Ltd. markets the ADORA2A antagonist Nouriast istradefylline to treat Parkinson’s disease...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article